Transforming Dermatology with AI

In a groundbreaking move for skin health, Skin Analytics has announced a major £15 million Series B funding round, spearheaded by Intrepid Growth Partners. This funding comes on the heels of their receipt of the Class III CE mark for their pioneering AI technology known as DERM, a device capable of independently diagnosing skin cancer.

The Future of Skin Cancer Detection is Here

Imagine a world where no one succumbs to skin cancer—Skin Analytics is on a mission to make that a reality. With DERM achieving an incredible 99.8% accuracy in ruling out skin cancer, the technology surpasses the 98.9% accuracy rate of traditional dermatologists. This innovation places Skin Analytics at the forefront of revolutionizing skin cancer detection.

Focus on Global Expansion and Accessibility

Utilizing the new funding, Skin Analytics aims to broaden its product range to address all dermatological issues and expand internationally, focusing on markets like Europe and Australia, where dermatologists are in short supply. This investment will also accelerate their entry into the U.S. market, promising a future where timely skin checks are accessible to all.

Combatting Dermatologist Shortages

Healthcare systems worldwide are grappling with a critical shortage of dermatologists, with some regions reporting only 30 dermatologists per million people. Skin-related conditions consistently rank among the top reasons for medical visits, underscoring the urgent need for solutions like DERM.

A Proven Impact in the UK

In the UK, Skin Analytics has already made significant strides. Their technology has been rolled out across 26 NHS sites, serving over 150,000 patients and detecting more than 14,000 cancers. DERM has proven capable of autonomously discharging up to 40% of suspected skin cancer referrals, thus relieving pressure on healthcare resources.

Expert Insights